UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 5.

Strasser, F; Blum, D; von Moos, R; Cathomas, R; Ribi, K; Aebi, S; Betticher, D; Hayoz, S; Klingbiel, D; Brauchli, P; Haefner, M; Mauri, S; Kaasa, S; Koeberle, D (2016). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Annals of Oncology, 27(2):324-332.

Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.

Rochlitz, C; Senn, H-J; Betticher, D; Helbling, D; von Moos, R; Pestalozzi, B; Thürlimann, B; Uebelhart, D; Aapro, M (2010). Der Einsatz von Bisphosphonaten bei der Behandlung solider Tumoren. Swiss Medical Forum, 10(34):562-564.

Ribi, K; Bernhard, J; Schuller, J C; Weder, W; Bodis, S; Jörger, M; Betticher, D; Schmid, R A; Stupp, R; Ris, H B; Stahel, R A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer, 61(3):398-404.

Lardinois, D; Suter, H; Hakki, H; Rousson, V; Betticher, D; Ris, H B (2005). Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Annals of Thoracic Surgery, 80(1):268-274.

This list was generated on Fri Jul 21 04:03:28 2017 CEST.